SCOTTSDALE, AZ -- (MARKET WIRE) -- January 30, 2007 -- Medistem Laboratories, Inc. (OTCBB: MDSM) (FRANKFURT: S2U) announced the publication of a peer reviewed paper proposing a novel approach for treatment of chronic myeloid leukemia using a clinically approved drug already on the market for unrelated symptoms. Chronic myeloid leukemia is a disease of the blood forming bone marrow stem cell. The disease affects 1 to 2 people per 100,000 and accounts for 7 - 20% cases of leukemia.
